Nanobiotix (NBTX) said late Tuesday it has closed its global offering, including the earlier full exercise by the underwriters of their option to buy additional new ordinary shares in the form of American depositary shares.

Following the full exercise of the underwriters' option, the global offering consisted of 2.2 million ordinary shares, including 225,373 ordinary shares in the form of ADSs, 33,805 ordinary shares in the form of additional ADSs, and 345,099 pre-funded warrants, according to the company.

Nanobiotix said the offering resulted in aggregate gross proceeds of approximately $100 million.

The company plans to use net proceeds from the global offering to support the development and advancement of JNJ-1900, to advance Nanoprimer and other platforms, and for general corporate purposes.